Table 1.
Baseline clinical and characteristics of patients
| rhBNP group (n=63) | Hydration group (n=63) | P value | |
|---|---|---|---|
| Age (years) | 59.35±9.01 | 60.37±9.26 | 0.534 |
| Gender | |||
| Male (%) | 38 (60.3) | 39 (61.9) | 0.855 |
| Female (%) | 25 (39.7) | 24 (38.1) | 0.855 |
| Body mass index (kg/m2) | 23.8 ± 3.7 | 24.1± 3.4 | 0.636 |
| Systolic blood pressure (mmHg) | 138.24±18.708 | 139.87±18.764 | 0.625 |
| Diastolic blood pressure (mmHg) | 85.73±11.261 | 87.35±11.597 | 0.428 |
| Hypertention (%) | 38 (60.3) | 41 (65.1) | 0.581 |
| Hyperlipemia (%) | 23 (36.5) | 23 (36.5) | 1.000 |
| Diabetes mellitus (%) | 13 (20.6) | 18 (28.6) | 0.301 |
| Smoking (%) | 19 (30.2) | 22 (34.9) | 0.568 |
| LVEF (%) | 61.81±3.12 | 61.51±2.97 | 0.580 |
| Durgs therapy | |||
| Calcium channel blocker (%) | 16 (25.4) | 24 (38.1) | 0.126 |
| β-Blocker (%) | 44 (69.8) | 49 (77.8) | 0.311 |
| Angiotensin converting enzyme inhibitor (%) | 23 (36.5) | 23 (36.5) | 1.000 |
rhBNP: Recombinant human brain natriuretic peptide; LVEF: Left ventricular ejection fraction.